79 related articles for article (PubMed ID: 29417951)
1. Erratum: Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod.
Neurol Neuroimmunol Neuroinflamm; 2018 Mar; 5(2):e445. PubMed ID: 29417951
[TBL] [Abstract][Full Text] [Related]
2. Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count.
Baharnoori M; Gonzalez CT; Chua A; Diaz-Cruz C; Healy BC; Stankiewicz J; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2018 Feb; 20():51-57. PubMed ID: 29304497
[TBL] [Abstract][Full Text] [Related]
3. Erratum: Dramatic rebounds of MS during pregnancy following fingolimod withdrawal.
Neurol Neuroimmunol Neuroinflamm; 2018 May; 5(3):e462. PubMed ID: 29666841
[TBL] [Abstract][Full Text] [Related]
4. The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis.
Wicks P; Rasouliyan L; Katic B; Nafees B; Flood E; Sasané R
BMC Res Notes; 2016 Sep; 9(1):434. PubMed ID: 27604188
[TBL] [Abstract][Full Text] [Related]
5. The changing multiple sclerosis treatment landscape: impact of new drugs and treatment recommendations.
Eriksson I; Komen J; Piehl F; Malmström RE; Wettermark B; von Euler M
Eur J Clin Pharmacol; 2018 May; 74(5):663-670. PubMed ID: 29429031
[TBL] [Abstract][Full Text] [Related]
6. Erratum to "A propensity-matched comparison of long-term disability worsening in patients with multiple sclerosis treated with dimethyl fumarate or fingolimod".
Ther Adv Neurol Disord; 2021; 14():17562864211044631. PubMed ID: 34539815
[TBL] [Abstract][Full Text] [Related]
7. Erratum: Lymphopenia and DMTs for relapsing forms of MS: Considerations for the treating neurologist.
Neurol Clin Pract; 2019 Jun; 9(3):184. PubMed ID: 31341703
[TBL] [Abstract][Full Text] [Related]
8. Erratum: Clinical and Demographic Characteristics and Two-Year Efficacy and Safety Data of 508 Multiple Sclerosis Patients with Fingolimod Treatment.
Terzi M; Helvacı EM; Şen S; Boz C; Çilingir V; Akçalı A; Beckmann Y; Uzunköprü C; Türkoğlu R; Yüceyar N; Efendi H; Destan Bünül S; Seferoğlu M; Kotan D; Güler S; Balcı BP; Öztürk B; Mungan S; İçen NK; Ömerhoca S; Yurtoğulları Ş; Sevim S; Türkoğlu ŞA; Çam M; Yetkin MF; Yoldaş TK; Sıvacı AÖ; Gökçe ŞF; Gürsoy E; Ünal A; Bilge N; Ağan K; Toprak MK; Koçer B; Sözer G; Terzi Y
Noro Psikiyatr Ars; 2023; 60(2):190. PubMed ID: 37287556
[TBL] [Abstract][Full Text] [Related]
9. Erratum: Glial cells express nuclear Nrf2 after fumarate treatment for multiple sclerosis and psoriasis.
Neurol Neuroimmunol Neuroinflamm; 2015 Jun; 2(3):e116. PubMed ID: 26015989
[TBL] [Abstract][Full Text] [Related]
10. Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.
Freedman MS; Montalban X; Miller AE; Dive-Pouletty C; Hass S; Thangavelu K; Leist TP
Mult Scler Relat Disord; 2016 Nov; 10():204-212. PubMed ID: 27919491
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.
Fox RJ; Chan A; Zhang A; Xiao J; Levison D; Lewin JB; Edwards MR; Marantz JL
Curr Med Res Opin; 2017 Feb; 33(2):175-183. PubMed ID: 27733070
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
[TBL] [Abstract][Full Text] [Related]
13. Severe multiple sclerosis reactivation during prolonged lymphopenia after dimethyl fumarate discontinuation.
Zecca C; Antozzi CG; Torri Clerici V; Ferrazzini M; Mantegazza RE; Rossi S; Gobbi C
Acta Neurol Scand; 2018 Jun; 137(6):623-625. PubMed ID: 29205270
[TBL] [Abstract][Full Text] [Related]
14. Erratum: Characterization of sputum biomarkers for asthma-COPD overlap syndrome [Erratum].
Int J Chron Obstruct Pulmon Dis; 2017; 12():1191. PubMed ID: 28458529
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T
J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up.
Hersh CM; Love TE; Cohn S; Hara-Cleaver C; Bermel RA; Fox RJ; Cohen JA; Ontaneda D
Mult Scler Relat Disord; 2016 Nov; 10():44-52. PubMed ID: 27919497
[TBL] [Abstract][Full Text] [Related]
17. Effects of dimethyl fumarate on lymphocyte subsets.
Berkovich R; Weiner LP
Mult Scler Relat Disord; 2015 Jul; 4(4):339-41. PubMed ID: 26195053
[TBL] [Abstract][Full Text] [Related]
18. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
Maruszczak MJ; Montgomery SM; Griffiths MJ; Bergvall N; Adlard N
J Med Econ; 2015; 18(11):874-85. PubMed ID: 26055952
[TBL] [Abstract][Full Text] [Related]
19. Role of dimethyl fumarate in oxidative stress of multiple sclerosis: A review.
Suneetha A; Raja Rajeswari K
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Apr; 1019():15-20. PubMed ID: 26899449
[TBL] [Abstract][Full Text] [Related]
20. Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.
Longbrake EE; Ramsbottom MJ; Cantoni C; Ghezzi L; Cross AH; Piccio L
Mult Scler; 2016 Jul; 22(8):1061-1070. PubMed ID: 26459150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
